News

< Back to News

CNCR ETF’s Position on Bristol-Myers Squibb’s Proposed Acquisition of Celgene

Mar. 6, 2019

After careful consideration, today the Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) announces its opposition to the acquisition of Celgene by Bristol-Myers Squibb. CNCR ETF has been a Bristol shareholder for more than three years and plans to vote its shares against the deal on behalf of CNCR’s shareholders. The fund has no position in Celgene currently. View all current holdings in the CNCR ETF.

CNCR ETF’s mission is to support cancer immunotherapy research and improved care for patients while giving investors exposure to one of the most innovative segments within the biotech industry. We take the responsibility that comes with this seriously. While we have no doubt Bristol’s management team is well intentioned, our opinion is that the acquisition is not in the best interest of cancer research, patients, or Bristol shareholders. The following five points bring us to this conclusion:

1. Bristol’s executive team is currently not suited to manage a larger organization.
In multiple cancer indications (particularly lung cancer), Bristol’s development plan for the immunotherapy drug Opdivo has been outclassed by its competitor Merck. Merck’s Keytruda and Bristol’s Opdivo are similar medicines (so much so that Bristol’s own management once described them as “Coke and Pepsi”), and it appears as though Opdivo’s recent development shortcomings are largely due to trial design and other management decision errors. Our confidence in the team’s ability to effectively manage Bristol-Myers Squibb has been reduced lately - let alone managing a much larger organization that would potentially include Celgene. As such, we believe that management has not earned the right to place this large bet with so much on the line.

2. Bristol should focus on making the investments it has already made a success.
Bristol has spent billions over the last few years on partnerships that it hopes will help regain its leadership position in immunotherapy. For example, one year ago it paid $1.85 billion up front and potentially billions more to partner with Nektar Therapeutics on NKTR-214. The companies have said they will soon commence 18 registration trials covering 12,000-15,000 patients, after testing the drug in only dozens of patients in early studies. Drug development is difficult and requires strict attention to detail. Given its recent struggles in the immunotherapy space, Bristol needs to focus on maximizing the investments it has already made and ensure these programs are positioned to have the best possible chance to succeed.

3. The deal will result in cuts to research and development (R&D) that we do not support.
Bristol has highlighted $2.5 billion in annual run-rate synergies as a key value driver of the deal, 35% of which will come from research and development (R&D). This type of cost cutting is not good for either company or the industry in general. While Bristol has said the synergies are mostly about reducing overlap, we are concerned that important research will not get funded because of it. Furthermore, we also believe the disruption that comes with integrating two organizations of this size is underappreciated and can set back research for years. We do not support such a large deal that will likely have a broad, negative impact on research.

4. We do not support Celgene’s past business practices and do not want to see Bristol go down the same path.
The cancer medicine REVLIMID accounts for over 60% of Celgene’s net product sales and the company has resorted to raising its price to an excessive degree. It did so an incredible three times in 2017, once in 2018, and once again at the beginning of 2019. This is outrageous and aggressive. We are concerned that Bristol will be motivated to keep REVLIMID’s revenue stream going for as long as possible in order to make the financials of the deal work. REVLIMID’s patent life is scheduled to expire in the coming years. It is not in the best interest of patients nor Bristol for the company to inherit an incentive to aggressively protect and promote the REVLIMID franchise.

5. Celgene’s poor stewardship of recent acquisitions suggests there is more risk in its pipeline than what is being presented at face value.
Celgene has a history lately of making major acquisitions and then seeing problems arise and stories change. The $7.2 billion acquisition of Receptos and $9 billion acquisition of Juno Therapeutics are two high-profile recent examples of deals that have experienced meaningful delays and turbulence soon after Celgene acquired them. We have a hard time agreeing with Bristol’s optimism about Celgene’s pipeline and the potential blockbusters they see coming to market. Given Celgene’s acquisitive history, there could be more risk to these programs succeeding than what is currently being presented at face value.

After a thorough review of the facts and careful consideration, we do not think Bristol-Myers Squibb acquiring Celgene is in the best interest of cancer research or for Bristol shareholders. Our fund has a responsibility to take an active interest in this matter and vote in a way that is consistent with our mission. While we appreciate the intentions of Bristol management, they have not fully illustrated they are capable of making the acquisition succeed or that Celgene is the right acquisition target. As a result, the CNCR ETF will be voting its shares AGAINST the deal.

Opinions expressed are those of the author, interviewee, or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Fund holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security. Celgene is not a holding of the Fund or affiliated with the Fund.


  • Loncar Funds
  • P.O Box 15072
  • Lenexa, KS 66285
  • +1 800-617-0004
  • Contact Us

CNCR Prospectus CHNA Prospectus

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 25 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 28 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained at www.loncarfunds.com. Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV. CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.